Phase I trials

A collection of phase I trials for investigational neurology and psychiatry drugs.

Submit your manuscript to this collection through the participating journal.

Journal

CNS Drugs

CNS Drugs provides researchers and healthcare professionals with essential information on the most important aspects of drug therapies used for the management of neurological and...

Submit to this journal Submission guidelines

Showing 1-3 of 3 articles

SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants
Andreas W. Wolff
Jörg Peine
Paul Lingor
Original Research Article Open access 28 February 2024 Pages: 291 - 302
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males
Markus Goettel
Rene Fuertig
Johan den Boer
Original Research Article Open access 29 November 2023 Pages: 1099 - 1109
Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies
René Fuertig
Markus Goettel
Vikas Sharma
Original Research Article Open access 29 November 2023 Pages: 1081 - 1097

Phase I trials

Participating journal

CNS Drugs

Articles

SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants

Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males

Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies

Navigation

Phase I trials

Participating journal

CNS Drugs

Articles

SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants

Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males

Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies

Search

Navigation